Endometrial hyperplasia historical perspective

Jump to: navigation, search

Endometrial hyperplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Endometrial hyperplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Case Studies

Case #1

Endometrial hyperplasia historical perspective On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Endometrial hyperplasia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endometrial hyperplasia historical perspective

CDC on Endometrial hyperplasia historical perspective

Endometrial hyperplasia historical perspective in the news

Blogs on Endometrial hyperplasia historical perspective

Directions to Hospitals Treating Endometrial hyperplasia

Risk calculators and risk factors for Endometrial hyperplasia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2]

Overview

The history of endometrial hyperplasia lays back to 1900s. Initially endometrial carcinoma was discovered and later on, on histological grades endometrial hyperplasia was explored.The association between estrogen and development of endometrial cancer was first reported in the 1970s when the incidence of endometrial cancer significantly increased between 1970 and 1975 following the introduction of estrogen replacement therapy.

Historical Perspective

Discovery

  • The earliest descriptions of endometrial cancer were reported in the early 1900s.
  • The association between estrogen and development of endometrial cancer was first reported in the 1970s when the incidence of endometrial cancer significantly increased between 1970 and 1975 following the introduction of estrogen replacement therapy.[1]
  • Surgical staging of endometrial cancer was first suggested in 1988 and was later revised in 2009.[2]
  • The first laparoscopic hysterectomy was reported in 1992.[3]

Landmark Events in the Development of Treatment Strategies

The current use of estrogen therapy (ET) and estrogen-progestin therapy (EPT) is the end result of many years of research and clinical practice.

References

  1. Jick H, Walker AM, Rothman KJ (1980). "The epidemic of endometrial cancer: a commentary". Am J Public Health. 70 (3): 264–7. PMC 1619376. PMID 7356090.
  2. Creasman W (2009). "Revised FIGO staging for carcinoma of the endometrium". Int J Gynaecol Obstet. 105 (2): 109. doi:10.1016/j.ijgo.2009.02.010. PMID 19345353.
  3. Childers JM, Surwit EA (1992). "Combined laparoscopic and vaginal surgery for the management of two cases of stage I endometrial cancer". Gynecol Oncol. 45 (1): 46–51. PMID 1534780.
  4. Brucker C (August 2001). "Controlled trial with a monthly combination injectable contraceptive in Europe". Gynecol. Endocrinol. 15 Suppl 3: 11–4. PMID 11570312.
  5. Smith DC, Prentice R, Thompson DJ, Herrmann WL (December 1975). "Association of exogenous estrogen and endometrial carcinoma". N. Engl. J. Med. 293 (23): 1164–7. doi:10.1056/NEJM197512042932302. PMID 1186789.
  6. Davis SR, Dinatale I, Rivera-Woll L, Davison S (May 2005). "Postmenopausal hormone therapy: from monkey glands to transdermal patches". J. Endocrinol. 185 (2): 207–22. doi:10.1677/joe.1.05847. PMID 15845914.
  7. Ettinger B (January 1998). "Overview of estrogen replacement therapy: a historical perspective". Proc. Soc. Exp. Biol. Med. 217 (1): 2–5. PMID 9421200.
  8. Ziel HK, Finkle WD (December 1975). "Increased risk of endometrial carcinoma among users of conjugated estrogens". N. Engl. J. Med. 293 (23): 1167–70. doi:10.1056/NEJM197512042932303. PMID 171569.
  9. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR (November 1980). "Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen". N. Engl. J. Med. 303 (21): 1195–8. doi:10.1056/NEJM198011203032102. PMID 7421945.

Linked-in.jpg